We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

56 hedge funds and large institutions have $23.5M invested in Viracta Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more call options, than puts

Call options by funds: $186K | Put options by funds: $87K

0% more funds holding

Funds holding: 56 → 56 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

3% less capital invested

Capital invested by funds: $24.2M → $23.5M (-$662K)

40% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 15

Holders
56
Holders Change
–
Holders Change %
0%
% of All Funds
1.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
15
Closed
6
Calls
$186K
Puts
$87K
Net Calls
+$99K
Net Calls Change
-$6K

Top Buyers

Rank Fund Capital Flow
1
First Eagle Investment Management
First Eagle Investment Management
New York
+$791K
2
Renaissance Technologies
Renaissance Technologies
New York
+$107K
3
Nomura Holdings
Nomura Holdings
Japan
+$14.2K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$11.2K
5
TSS
Two Sigma Securities
New York
+$11.1K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.87M
2
BFA
BlackRock Fund Advisors
California
-$69.7K
3
GPP
Great Point Partners
Connecticut
-$40.1K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$31.8K
5
DCM
Driehaus Capital Management
Illinois
-$17.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
GPP
1
Great Point Partners
Connecticut
$4.48M -$40.1K -362 -0.9%
NMC
2
NEA Management Company
Maryland
$4.28M – – –
PAI
3
Palo Alto Investors
California
$3.82M – – –
BI
4
BVF Inc
California
$2.64M – – –
BBA
5
Baker Bros. Advisors
New York
$2.44M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.37M +$11.2K +101 +0.9%
DCM
7
Driehaus Capital Management
Illinois
$1.07M -$17.9K -162 -2%
First Eagle Investment Management
8
First Eagle Investment Management
New York
$822K +$791K +7,143 New
Fidelity Investments
9
Fidelity Investments
Massachusetts
$314K -$1.87M -16,868 -86%
FWM
10
Frontier Wealth Management
Missouri
$259K -$8.2K -74 -3%
BIT
11
BlackRock Institutional Trust
California
$252K – – –
DCM
12
DAFNA Capital Management
California
$232K – – –
Federated Hermes
13
Federated Hermes
Pennsylvania
$219K – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$186K – – –
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$163K -$12.6K -114 -7%
Renaissance Technologies
16
Renaissance Technologies
New York
$149K +$107K +963 +288%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$126K -$2.22K -20 -2%
FSA
18
Franklin Street Advisors
North Carolina
$110K – – –
Deutsche Bank
19
Deutsche Bank
Germany
$71K – – –
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$64K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$61K -$31.8K -287 -35%
Group One Trading
22
Group One Trading
Illinois
$54K +$332 +3 +0.6%
Northern Trust
23
Northern Trust
Illinois
$49K -$3.99K -36 -8%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$33K +$665 +6 +2%
Goldman Sachs
25
Goldman Sachs
New York
$29K +$111 +1 +0.4%
1
2 3

VIRX Hedge Fund Activity: Q2 2016 in Review

56 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2016, worth a combined $23.5M — down 2.7% from $24.2M a quarter earlier.

Fund positioning in VIRX was balanced in Q2 2016: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 15 trimmed.

The largest buyer was First Eagle Investment Management, opening a new position worth an estimated $791K. The largest seller was Fidelity Investments, cutting an estimated $1.87M.

  • 56 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $23.5M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2016, down 2.7% quarter-over-quarter.
  • 6 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2016 and 6 closed out, a net change of 0 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2016 was First Eagle Investment Management, an estimated $791K added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2016 was Fidelity Investments, an estimated $1.87M sold.

Based on aggregated 13F filings for Q2 2016.